Jinghua Pharmaceutical Group Co., Ltd. (002349.SZ)
- Previous Close
7.40 - Open
7.68 - Bid 7.50 x --
- Ask 7.51 x --
- Day's Range
7.40 - 7.57 - 52 Week Range
5.88 - 11.09 - Volume
9,421,409 - Avg. Volume
14,609,387 - Market Cap (intraday)
6.114B - Beta (5Y Monthly) --
- PE Ratio (TTM)
25.03 - EPS (TTM)
0.30 - Earnings Date --
- Forward Dividend & Yield 0.08 (1.07%)
- Ex-Dividend Date Jun 9, 2023
- 1y Target Est
--
Jinghua Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, and sale of APIs and pharmaceutical intermediates in China. Its primary products include Phenylbutazone, Primidone, Phenobarbital, Fluorouracil, Propylthiouracil, Piroxicam, and Flucytosine APIs. The company was formerly known as Nantong Jinghua Pharmaceutical Co., Ltd. The company was founded in 1957 and is based in Nantong, China.
www.jinghuapharm.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 002349.SZ
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002349.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002349.SZ
Valuation Measures
Market Cap
6.11B
Enterprise Value
4.90B
Trailing P/E
24.69
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.05
Price/Book (mrq)
2.50
Enterprise Value/Revenue
3.24
Enterprise Value/EBITDA
11.73
Financial Highlights
Profitability and Income Statement
Profit Margin
16.39%
Return on Assets (ttm)
6.24%
Return on Equity (ttm)
10.19%
Revenue (ttm)
1.51B
Net Income Avi to Common (ttm)
247.7M
Diluted EPS (ttm)
0.30
Balance Sheet and Cash Flow
Total Cash (mrq)
1.24B
Total Debt/Equity (mrq)
0.80%
Levered Free Cash Flow (ttm)
142.1M